Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.

Torge, Afra; Wagner, Stefanie; Chaves, Paula S; Oliveira, Edilene G; Guterres, Silvia S; Pohlmann, Adriana R; Titz, Alexander; Schneider, Marc; Beck, Ruy C R

dc.contributor.author	Torge, Afra
dc.contributor.author	Wagner, Stefanie
dc.contributor.author	Chaves, Paula S
dc.contributor.author	Oliveira, Edilene G
dc.contributor.author	Guterres, Silvia S
dc.contributor.author	Pohlmann, Adriana R
dc.contributor.author	Titz, Alexander
dc.contributor.author	Schneider, Marc
dc.contributor.author	Beck, Ruy C R
dc.date.accessioned	2017-06-06T14:47:00Z
dc.date.available	2017-06-06T14:47:00Z
dc.date.issued	2017-05-10
dc.identifier.citation	Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis. 2017, 527 (1-2):92-102 Int J Pharm	en
dc.identifier.issn	1873-3476
dc.identifier.pmid	28499793
dc.identifier.doi	10.1016/j.ijpharm.2017.05.013
dc.identifier.uri	http://hdl.handle.net/10033/620934
dc.description.abstract	Treatment of bacterial airway infections is essential for cystic fibrosis therapy. However, effectiveness of antibacterial treatment is limited as bacteria inside the mucus are protected from antibiotics and immune response. To overcome this biological barrier, ciprofloxacin was loaded into lipid-core nanocapsules (LNC) for high mucus permeability, sustained release and antibacterial activity. Ciprofloxacin-loaded LNC with a mean size of 180nm showed a by 50% increased drug permeation through mucus. In bacterial growth assays, the drug in the LNC had similar minimum inhibitory concentrations as the free drug in P. aeruginosa and S. aureus. Interestingly, formation of biofilm-like aggregates, which were observed for S. aureus treated with free ciprofloxacin, was avoided by exposure to LNC. With the combined advantages over the non-encapsulated drug, ciprofloxacin-loaded LNC represent a promising drug delivery system with the prospect of an improved antibiotic therapy in cystic fibrosis.
dc.language.iso	en	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/4.0/	*
dc.title	Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.	en
dc.type	Article	en
dc.contributor.department	Helmholtz Institut für pharmazeutische Forschung Saarland, Universitätscampus E8.1, 66123 Saarbrücken, Germany.	en
dc.identifier.journal	International journal of pharmaceutics	en
refterms.dateFOA	2018-07-15T00:00:00Z
html.description.abstract	Treatment of bacterial airway infections is essential for cystic fibrosis therapy. However, effectiveness of antibacterial treatment is limited as bacteria inside the mucus are protected from antibiotics and immune response. To overcome this biological barrier, ciprofloxacin was loaded into lipid-core nanocapsules (LNC) for high mucus permeability, sustained release and antibacterial activity. Ciprofloxacin-loaded LNC with a mean size of 180nm showed a by 50% increased drug permeation through mucus. In bacterial growth assays, the drug in the LNC had similar minimum inhibitory concentrations as the free drug in P. aeruginosa and S. aureus. Interestingly, formation of biofilm-like aggregates, which were observed for S. aureus treated with free ciprofloxacin, was avoided by exposure to LNC. With the combined advantages over the non-encapsulated drug, ciprofloxacin-loaded LNC represent a promising drug delivery system with the prospect of an improved antibiotic therapy in cystic fibrosis.